Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO1990012585 - METHODS FOR CONTROLLING HUMAN ENDOTHELIAL CELL PROLIFERATION AND EFFECTOR FUNCTIONS USING ONCOSTATIN M

Publication Number WO/1990/012585
Publication Date 01.11.1990
International Application No. PCT/US1990/001907
International Filing Date 09.04.1990
IPC
A61K 38/19 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
A61K 47/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
CPC
A61K 38/1841
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
1841Transforming growth factor [TGF]
A61K 38/204
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins [IL]
204IL-6
A61K 38/49
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
48acting on peptide bonds (3.4)
49Urokinase; Tissue plasminogen activator
A61K 47/642
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
642the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
A61K 47/6813
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
6811the drug being a protein or peptide, e.g. transferrin or bleomycin
6813the drug being a peptidic cytokine, e.g. an interleukin or interferon
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants
  • ONCOGEN LIMITED PARTNERSHIP [US]/[US]
Inventors
  • BROWN, Thomas, J.
  • GLADSTONE, Paul, R.
Agents
  • MISROCK, S., Leslie
Priority Data
335,39910.04.1989US
504,48604.04.1990US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR CONTROLLING HUMAN ENDOTHELIAL CELL PROLIFERATION AND EFFECTOR FUNCTIONS USING ONCOSTATIN M
(FR) PROCEDES POUR MAITRISER LA PROLIFERATION DE CELLULES ENDOTHELIALES HUMAINES ET FONCTIONS EFFECTRICES UTILISANT L'ONCOSTATINE M
Abstract
(EN)
The present invention is directed to the use of a recently discovered cytokine, Oncostatin M, to control endothelial cell immunogenicity, fibrinolytic activity, proliferation and cytokine synthesis, and to its use in the treatment of a variety of human vascular and immune system disorders involving the vascular endothelium, as well as its use in the treatment of neoplastic disease. The method of the invention includes the use of mature, hybrid, modified or truncated forms of Oncostatin M as well as Oncostatin M analogs. The invention is described by way of examples in which the efficacy of such compounds is evaluated using various $i(in vitro) assay systems.
(FR)
L'invention concerne l'emploi d'une cytokine récemment découverte, l'oncostatine M, pour maîtriser le pouvoir immunogène, l'activité fribrinolytique, la prolifération ainsi que la synthèse de la cytokine des cellules endothéliales, ainsi que son emploi dans le traitement d'une variété de troubles du système vasculaire et immunitaire humain touchant l'endothélium vasculaire, et son emploi dans le traitement de maladies néoplasiques. Le procédé de l'invention comprend l'emploi de formes mûres, hybrides, modifiées ou tronquées de l'oncostatine M ainsi que d'analogues de l'oncostatine M. L'invention est illustrée par des exemples dans lesquels l'efficacité desdits composés est évaluée à l'aide de divers systèmes d'analyse $i(in vitro).
Latest bibliographic data on file with the International Bureau